Healthcare

In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.

In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries.

On April 11, 2018, Pfizer (PFE) said its ATLAS trial with Inlyta failed to show improvement in RCC disease-free survival.

Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.

In 4Q17, Novartis’s (NVS) Galvus generated revenues of $327 million, which is ~10% growth on a year-over-year (or YoY) basis and 5% growth quarter-over-quarter.

Merck reported 3% growth in revenues to ~$10.4 billion during 4Q17 as compared to 4Q16.

In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.

Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.

On February 20, 2018, Teva Pharmaceutical announced the US launch of the generic version of Solodyn Extended Release tablets in two strengths.

On February 9, 2018, Teva Pharmaceuticals (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules.

Dentsply Sirona (XRAY) has delivered lower merger synergies than the company had estimated. It also took an impairment charge during 4Q17.

In 2018, LHC Group is expected to report revenue of $1.2 billion. What about its peers?

Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with reported EPS of $4.86 as compared to estimates of $4.82 for 2017.

To better position itself and compete effectively in this evolving healthcare environment, Tenet Healthcare has taken a number of steps.

On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.

Masimo’s future growth strategy is focused on international expansion opportunities in Europe, Asia, Asia-Pacific, the Middle East, and Latin America.

Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

In November 2017, Novo Nordisk (NVO) submitted an application to European regulatory authorities to update Xultophy’s label.

Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.

Novo Nordisk has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among general practitioners and primary care physicians.

Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow.

In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status.

AmerisourceBergen’s (ABC) operations are organized based on the products and services it provides to customers.

According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.

In 3Q17, Novo Nordisk managed to update Victoza’s label in the United States and Europe.

On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced FDA approval for the expanded indication for Acclarent Aera.

Boston Scientific (BSX) operates in three business segments that cater to seven different product categories.

Integer Holdings Corporation provides custom battery packs to energy, military, and environmental markets for use in extreme environments.

Edwards Lifesciences’ (EW) products can be categorized into three therapeutic areas: transcatheter heart valve, surgical heart valve, and critical care.

Between November 22 and February 21, Universal Health Services stock has risen 19% to reach $117.

Cardiac and Vascular Group in fiscal 4Q17 Medtronic (MDT) reported total sales of ~$7.4 billion in fiscal 3Q18. Of that total, ~38% (~$2.8 billion) was contributed by Medtronic’s CVG (Cardiac and Vascular Group). CVG sales grew ~10% YoY (year-over-year) and ~7% on a constant-currency basis. US CVG sales grew ~6% YoY, while developed nation CVG sales […]

The top three drugstore chains in the US are in the process of forming new associations through mergers and acquisitions to create a more diversified portfolio and protect themselves from the growing online threat.

Vanda Pharmaceuticals’ (VNDA) Hetlioz was approved by the FDA in January 2014 for the treatment of Non-24-Hour Sleep Wake Disorder.

Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development.

In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.

On February 15, 2018, GlaxoSmithKline traded at a forward PE multiple of 12.9x, which is lower than the industry average of 13.3x.

Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.

Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.